ArticleCancer immunology, immunotherapy : CII2024

Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.

Cuicui Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.